Arman Rahmim, PhD, DABSNM, FSNMMI

In the Name of God

Dr. Rahmim is Professor of Radiology, Physics and Biomedical Engineering at the University of British Columbia (UBC), as well as Distinguished Scientist and Provincial Medical Imaging Physicist at BC Cancer. He received his MSc in condensed matter physics and PhD in medical imaging physics at UBC. He was then recruited by Johns Hopkins University (JHU), leading the high-resolution brain PET imaging physics program and pursuing research at the JHU Departments of Radiology and Electrical Engineering. In 2018, he was recruited back to Vancouver, where his laboratory (Qurit Lab) pursues research in molecular imaging & therapy. He has published a book and over 300 journal articles, and delivered more than 180 invited lectures worldwide. He also hosts the Molecular Imaging & Therapy YouTube channel to help disseminate learning for a wide worldwide audience including students, residents, fellows and technologists. He is Scientific Lead of the BC Cancer Medical Imaging Core (CanMIC) Lab, aiming to translate state-of-the-art imaging solutions to clinical trials and research. Additionally, he is Co-Founder and Chief Scientific Officer of Ascinta Technologies, working to develop easy-to-use, adaptable, and AI-enabled solutions for theranostics and radiopharmaceutical therapies. Dr. Rahmim was awarded in 2016 the John S. Laughlin Young Scientist Award by the American Association of Physicists in Medicine (AAPM), in 2022 the Presidential Distinguished Service Award by the Society of Nuclear Medicine & Molecular Imaging (SNMMI) for significant contributions to the field of nuclear medicine & molecular imaging, and in 2025 the prestigious SNMMI Edward J. Hoffman Memorial Award for outstanding contributions to computational nuclear medicine research, best-practice, training and education. He has served as Vice President (2017-18) and President (2018-19) of the SNMMI Physics, Instrumentation and Data Sciences Council (PIDSC), as well as Chair of the AI Task Force (2020-2024) and the Dosimetry-AI working group (2022-present).